GLP-1 Medications and Hidradenitis Suppurativa: A Promising Connection
How GLP-1 weight loss medications may help manage hidradenitis suppurativa through weight loss and anti-inflammatory effects, plus treatment coordination guidance.
More on Health Conditions
Important Medical Disclaimer
This article is for informational purposes only. HS is a chronic inflammatory skin condition requiring dermatological management. Coordinate GLP-1 therapy with your dermatologist.
The HS-Obesity-Inflammation Triangle
Hidradenitis suppurativa is a chronic inflammatory skin condition causing painful nodules, abscesses, and tunnels in areas like the armpits, groin, and under breasts. Obesity is both a risk factor and an aggravating factor for HS, creating a cycle of inflammation, pain, reduced mobility, weight gain, and worsened disease.
Up to 75% of HS patients are overweight or obese. Excess weight increases skin-on-skin friction in HS-prone areas, elevates systemic inflammatory markers that drive HS flares, worsens hormonal imbalances (insulin resistance, androgen levels) that contribute to HS pathology, and reduces the effectiveness of HS treatments.
GLP-1 medications like semaglutide ($99/mo compounded at Trimi) and tirzepatide ($125/mo compounded) address multiple HS drivers simultaneously: they promote weight loss (reducing friction and mechanical triggers), improve insulin sensitivity (addressing metabolic contributors), and reduce systemic inflammation.
How Weight Loss Helps HS
Reduced Friction
Weight loss decreases skin fold depth and skin-on-skin contact in axillary, inguinal, and inframammary areas where HS lesions commonly occur.
Lower Inflammatory Burden
Adipose tissue produces pro-inflammatory cytokines (TNF-alpha, IL-1beta, IL-17) directly implicated in HS pathogenesis. Reducing fat mass reduces this inflammatory fuel.
Improved Insulin Sensitivity
Insulin resistance and metabolic syndrome are strongly associated with HS severity. GLP-1 medications improve insulin sensitivity independently of weight loss, providing additional benefit.
Better Treatment Response
Research shows HS biologics (like adalimumab) work better in patients with lower BMI. Weight loss from GLP-1 therapy may enhance the effectiveness of your HS-specific treatments.
Practical Guidance
1. Choose Injection Sites Carefully
Inject only into skin free of HS lesions, tunnels, or scars. The abdomen is usually the best option. Never inject into inflamed or infected tissue.
2. Maintain Wound Care During GLP-1 Therapy
Continue your HS wound care regimen. Adequate protein intake (essential for wound healing) is critical -- do not let GLP-1 appetite suppression compromise your protein goals.
3. Track HS Severity Alongside Weight
Document flare frequency, lesion count, and pain levels as you lose weight. This data helps your dermatologist adjust HS treatments and demonstrates the therapeutic value of weight management.
4. Consider Anti-Inflammatory Eating
Some HS patients find that reducing dairy, refined sugars, and yeast in combination with GLP-1 therapy produces better results. Work with a dietitian familiar with HS dietary approaches.
Frequently Asked Questions
Can weight loss from GLP-1 medications improve hidradenitis suppurativa?
Yes, significantly. Obesity is one of the strongest modifiable risk factors for HS severity. Studies show that 10-15% weight loss can reduce HS flare frequency by 30-50%, decrease lesion severity, and improve quality of life. Weight loss reduces skin friction, hormonal drivers, and systemic inflammation.
Do GLP-1 medications have direct anti-inflammatory effects on HS?
While not studied specifically in HS, GLP-1 medications reduce systemic inflammatory markers (TNF-alpha, IL-6, CRP) that are elevated in HS. Combined with the anti-inflammatory effects of weight loss, GLP-1 therapy may provide dual benefit for HS management.
Can I inject GLP-1 medication near HS lesions?
No. Avoid injecting into areas with active HS lesions, tunnels, or scars. Choose injection sites free of HS involvement -- typically the abdomen is the safest choice if your HS primarily affects axillary or groin areas. Rotate among unaffected sites.
Will GLP-1 medications interact with HS treatments?
GLP-1 medications may alter absorption of oral antibiotics (doxycycline, clindamycin) used for HS due to delayed gastric emptying. Injectable biologics (adalimumab, secukinumab) for HS are not affected. Hormonal treatments (spironolactone, oral contraceptives) may also have altered absorption.
How quickly might I see HS improvement with GLP-1-assisted weight loss?
HS improvement typically correlates with the amount of weight lost rather than the speed. Most patients begin noticing fewer flares after 10-15 pounds of weight loss (typically 2-4 months into GLP-1 therapy). Significant improvement often occurs at 15-20% body weight loss.
Address HS at Its Root With Weight Management
Weight loss can transform your HS management. Semaglutide from $99/mo, tirzepatide from $125/mo.
Explore Treatment OptionsSources & References
- Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. NEJM 2021;384:989-1002.
- Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. NEJM 2022;387:205-216.
- Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. NEJM 2023;389:2221-2232.
- FDA Prescribing Information for Wegovy (semaglutide) and Zepbound (tirzepatide).